Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis

Catherine M. Ludwig, Jennifer L. Hsiao, Peter A. Lio, Vivian Y. Shi

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically - tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.

Original languageEnglish
Pages (from-to)S4-S7
Issue number1
StatePublished - 1 Oct 2021
Externally publishedYes


Dive into the research topics of 'Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this